Michael Howell Acquires 7,987 Shares of Zura Bio Limited (NASDAQ:ZURA) Stock

Zura Bio Limited (NASDAQ:ZURA) insider Michael Howell acquired 7,987 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The stock was bought at an average cost of $3.13 per share, for a total transaction of $24,999.31. Following the completion of the transaction, the insider now directly owns 7,987 shares in the company, valued at approximately $24,999.31. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Zura Bio Trading Down 4.9 %

ZURA traded down $0.17 during trading on Wednesday, hitting $3.31. The company had a trading volume of 826,726 shares, compared to its average volume of 278,140. Zura Bio Limited has a one year low of $2.00 and a one year high of $14.00. The firm’s 50-day moving average price is $3.21 and its 200 day moving average price is $4.04.

Institutional Investors Weigh In On Zura Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Forefront Analytics LLC lifted its position in Zura Bio by 46.8% during the 4th quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock worth $99,000 after buying an additional 6,765 shares in the last quarter. Raymond James & Associates lifted its position in Zura Bio by 14.0% during the 3rd quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock worth $511,000 after buying an additional 9,481 shares in the last quarter. Lynx1 Capital Management LP bought a new stake in Zura Bio during the 3rd quarter worth about $65,000. Bank of New York Mellon Corp bought a new stake in Zura Bio during the 3rd quarter worth about $224,000. Finally, Eisler Capital US LLC bought a new stake in Zura Bio during the 3rd quarter worth about $660,000. 61.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $16.00 price objective (down from $17.00) on shares of Zura Bio in a research report on Monday, April 1st. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $16.40.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.